FASN and prostate carcinoma: The effectiveness of the FASNi GSK2194069 against breast and prostate cancer cells was significantly compromised if macropinocytic cells had access to necrotic cell debris (Fig. 3e–i); if fatty acids can be scavenged from the tumor microenvironment, cells will no longer be dependent on FASN.